SPINOCEREBELLAR ATAXIA

Spinocerebellar Ataxia — 40+ genetic subtypes of progressive cerebellar degeneration, where antisense oligonucleotide trials are advancing rapidly and molecular subtype identification determines eligibility for gene-specific therapies.

Whole genome sequencing evaluates all 40+ SCA genes — including CAG repeat expansions (SCA1/2/3/6/7/17), non-coding repeat expansions (SCA8/10/36), and conventional mutations (SCA5/11/13/14) — in a single comprehensive analysis.

ATXN3
ATXN2
ATXN1
CACNA1A
ATXN7

About this condition

Spinocerebellar Ataxia

Spinocerebellar ataxias (SCAs) are a group of over 40 autosomal dominant progressive cerebellar degenerative disorders, numbered SCA1 through SCA48+ as new genes are identified. The most common SCAs worldwide are SCA3/Machado-Joseph disease (ATXN3 CAG expansion, ~21% globally), SCA2 (ATXN2 CAG expansion, ~15%), SCA6 (CACNA1A CAG expansion, ~15%), SCA1 (ATXN1 CAG expansion, ~6%), and SCA7 (ATXN7 CAG expansion, ~5%). Combined SCA prevalence is approximately 1-5 per 100,000, varying by population and geography.

SCAs present with progressive cerebellar ataxia (gait unsteadiness, dysarthria, oculomotor abnormalities) with variable additional features depending on the specific subtype: SCA1 and SCA2 include pyramidal signs and peripheral neuropathy; SCA3 includes dystonia, ophthalmoplegia, and parkinsonism; SCA6 is a pure cerebellar ataxia with late onset; SCA7 includes progressive retinal degeneration (the only SCA with macular dystrophy). Age of onset correlates inversely with repeat expansion length (anticipation — longer repeats cause earlier onset in successive generations, particularly through paternal transmission).

Antisense oligonucleotide (ASO) therapies targeting the polyglutamine-encoding mRNA transcripts are in clinical trials for SCA1, SCA2, and SCA3 — the three most common polyglutamine SCAs. These gene-silencing approaches aim to reduce toxic protein production. Additionally, ion channel modulators and small molecules targeting downstream cerebellar degeneration pathways are being evaluated. All trials require confirmed molecular SCA subtype for enrollment. The importance of early molecular diagnosis extends beyond current trial enrollment: natural history studies establishing outcome measures for future trials also require genotyped participants.

SCA7 is the only SCA with retinal degeneration — any patient with progressive ataxia plus macular dystrophy should have ATXN7 repeat testing. The retinal component can precede the ataxia, mimicking isolated retinal dystrophy.

Gene locus: ATXN3 (14q32.12), ATXN2 (12q24.12), ATXN1 (6p22.3), CACNA1A (19p13.13), ATXN7 (3p14.1)

40+ SCA subtypes cannot be tested sequentially. Repeat expansion detection technology now enables WGS to identify CAG expansions and non-coding repeats that historically required specialized assays.

ASO therapies for SCA1/2/3 in clinical trials — molecular subtype determines eligibility for gene-specific silencing approaches

Antisense oligonucleotides designed to silence ATXN1 (SCA1), ATXN2 (SCA2), or ATXN3 (SCA3) mRNA are gene-specific — an SCA1 ASO does not treat SCA3, and vice versa. Clinical trial enrollment requires confirmed molecular diagnosis with documented repeat expansion length. Without molecular subtyping, patients with clinically indistinguishable progressive cerebellar ataxia cannot access gene-specific trials. WGS identifies the specific SCA subtype from a single test, ending the stepwise single-gene testing that delays trial enrollment.

Anticipation means that children of SCA patients may develop symptoms decades earlier — presymptomatic testing enables planning and future trial enrollment

CAG repeat expansions in SCA1/2/3/7 exhibit anticipation — intergenerational repeat instability (particularly through paternal transmission) produces longer repeats in offspring, causing earlier onset and more severe disease. A parent with SCA3 onset at age 45 may have a child with onset at age 25. Presymptomatic testing identifies at-risk family members before symptom onset, enabling enrollment in prevention trials, life planning, and immediate clinical trial access when symptoms begin. Genetic counseling before presymptomatic testing is essential.

Spinocerebellar Ataxia — 40+ genetic subtypes of progressive cerebellar degeneration, where antisense oligonucleotide trials are advancing rapidly and molecular subtype identification determines eligibility for gene-specific therapies.

Spinocerebellar Ataxia

40+ SCA subtypes cannot be tested sequentially. Repeat expansion detection technology now enables WGS to identify CAG expansions and non-coding repeats that historically required specialized assays.

ASO therapies for SCA1/2/3 in clinical trials — molecular subtype determines eligibility for gene-specific silencing approaches

Anticipation means that children of SCA patients may develop symptoms decades earlier — presymptomatic testing enables planning and future trial enrollment

Others in Neurological

One test. A lifetime of answers.